Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RENX vs CDIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDIO Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 7–1 Matrix Metrics)

CDIO Overall Winner 6-Pillar Tally: RENX 0 – 3 CDIO (3 Tie) Matrix Metrics: RENX 1 – 7 CDIO

As of Nov 20, 2026, Cardio Diagnostics Holdings Inc. (CDIO) is the stronger overall head-to-head candidate over RENX (RENX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RENX carries a Unified Composite Score of 44.0/100 (HOLD) at $0.74 (N/M Forward P/E, N/A operating margin), whereas CDIO carries 47.2/100 (HOLD) at $1.60 (N/M Forward P/E, -42649.8% operating margin).

  • Technical & Structure Timing Caution: RENX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.6); meanwhile CDIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RENX vs CDIO
RENX US Equity
RENX
Institutional Equity
$0.74
-23.09% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.85β · 161% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.4%), weak momentum, RSI 32
RSI-14: 31.6 · SMA20: $1.05 · SMA50: $1.49
CDIO NASDAQ Head-to-Head Winner
Cardio Diagnostics Holdings Inc. Common stock
In Vitro & In Vivo Diagnostic Substances
$1.60
-3.03% 1D
Market Cap $4.9M
TTM Revenue $15,185
Forward P/E N/M
Beta / 30D Vol 1.36β · 56% Vol
Unified Composite Score
47.2 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 39
RSI-14: 38.6 · SMA20: $1.73 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (RENX 0 – 3 CDIO)

Columns: Metric · RENX · CDIO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CDIO
Revenue Growth (YoY) N/A +25.7%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $15,185
Market Cap N/A $4.9M
3. Profitability & Quality CDIO
Gross Margin N/A 100.0%
Operating Margin N/A -42649.8%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -93.5%
4. Balance Sheet & Cash Flow CDIO
Cash Generation (TTM) N/A -$6.3M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $6.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RENX (1) vs CDIO (7)
Institutional Metric RENX CDIO Criterion Row Edge
Market Capitalization
Scale
N/A $4.9M Larger Scale CDIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +25.7% Higher Growth CDIO
Operating Margin (TTM)
Profitability
N/A -42649.8% Higher Margin CDIO
Net Profit Margin
Profitability
N/A 0.0% Higher Margin CDIO
Return on Equity (ROE)
Capital Efficiency
N/A -93.5% Higher ROE CDIO
52-Week Range Position
Momentum
19% ($0–$3) 9% ($1–$8) Stronger Trend RENX
Beta / 30D Volatility
Risk Regime
-17.85β · 161% Vol 1.36β · 56% Vol Lower Realized Risk CDIO
Unified Institutional Score
Composite Signal
44.0 / 100 (HOLD) 47.2 / 100 (HOLD) Higher Composite CDIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $15,185 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$6.3M ($6.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDIO +42.05 pp
RENX: -48.21% · CDIO: -6.16%
3M Horizon CDIO +45.79 pp
RENX: -62.67% · CDIO: -16.88%
6M Horizon CDIO +51.93 pp
RENX: -52.55% · CDIO: -0.62%
1Y Horizon RENX +212.13 pp
RENX: +163.58% · CDIO: -48.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RENX vs CDIO. Trailing 12-month operating profitability (RENX N/A vs CDIO -42649.8%) and valuation multiples (RENX N/M vs CDIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RENX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CDIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$15,185
Gross Margin100.0%
Op. Margin-42649.8%
ROE / Fwd P/E-93.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RENX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RENX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RENX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.9M market capitalization and -42649.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RENX vs CDIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Cardio Diagnostics Holdings Inc. (CDIO) is the stronger overall head-to-head candidate over RENX (RENX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RENX carries a Unified Composite Score of 44.0/100 (HOLD) at $0.74 (N/M Forward P/E, N/A operating margin), whereas CDIO carries 47.2/100 (HOLD) at $1.60 (N/M Forward P/E, -42649.8% operating margin). Technical & Structure Timing Caution: RENX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.6); meanwhile CDIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDIO leads the Growth & Scale pillar: RENX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CDIO at +25.7% YoY revenue growth and +0.0% YoY earnings growth on $15,185 TTM revenue (100.0% gross margin, -42649.8% operating margin). On trailing 12-month operating scale, RENX generates N/A in USD-normalized revenue versus $15,185 for CDIO. In operating R&D and SG&A reinvestment, RENX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CDIO.

RENX and CDIO trade at balanced relative valuation multiples. RENX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CDIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RENX (N/A ROE) versus CDIO (-93.5% ROE) capital efficiency.

In options market volatility and institutional positioning, RENX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-17.85β · 161% Vol realized risk). By comparison, CDIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.